Recommended Pages at ash.confex.com
Paper: Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study
ash.confex.com — “Paper: Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study” View full resource at ash.confex.com
Most Recently Shared on December 13, 2010 at 2:52 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Data from ASH: Elotuzumab + Revlimid/dexamethasone produced 85% response rate in patients with relapsed myeloma (http://bit.ly/enfUn8).
Paper: Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils
ash.confex.com — “Paper: Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils” View full resource at ash.confex.com
Most Recently Shared on December 6, 2010 at 3:52 pm By:
Mesenchymal SC-based expansion of umbilical cord blood cells speeds transplant engraftment http://bit.ly/gya6pu #AHS2010 #ASH_hematology
Paper: Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study
ash.confex.com — “Paper: Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study” View full resource at ash.confex.com
Most Recently Shared on December 5, 2010 at 4:03 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
ASH data: Using antibiotics as prophylaxis for infections in myeloma patients didn't actually reduce their frequency (http://bit.ly/ijk4hq).
Paper: Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Mul
ash.confex.com — “Paper: Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial” View full resource at ash.confex.com
Most Recently Shared on December 5, 2010 at 3:52 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
ASH data: Autologous transplant followed by allogeneic no better in terms of survival than double auto (http://bit.ly/hAgoi0).
Paper: HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)
ash.confex.com — “Paper: HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM)” View full resource at ash.confex.com
Most Recently Shared on December 5, 2010 at 3:50 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
ASH data: Induction with bortezomib-containing regimen, transplant, and bortezomib maintenance -> superior outcomes (http://bit.ly/faUXxq).
Paper: Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial
ash.confex.com — “Paper: Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial” View full resource at ash.confex.com
Most Recently Shared on December 5, 2010 at 3:42 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
ASH data: Early transplant after lenalidomide/dexamethasone gave better long-term outcome than continued len/dex (http://bit.ly/gywCbc).
Paper: Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma
ash.confex.com — “Paper: Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma” View full resource at ash.confex.com
Most Recently Shared on December 3, 2010 at 3:15 pm By:
Physician Relations Health Organization
RT @Myeloma_Doc Retreatment with immunomodulatory agent after previous exposure can be efficacious for multiple myeloma http://bit.ly/g6d2pD
Paper: Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients
ash.confex.com — “Paper: Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients” View full resource at ash.confex.com
Most Recently Shared on December 3, 2010 at 3:07 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Lenalidomide is associated with a 4.6% incidence of neuropathy, but only 1.1% episodes grade 3/4 (moderate to severe)(http://bit.ly/euc69V).
Paper: A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
ash.confex.com — “Paper: A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma” View full resource at ash.confex.com
Most Recently Shared on November 30, 2010 at 2:10 am By:
Robert Z. Orlowski Physician, Doctor, and Internist
Data to be presented at ASH comparing intravenous and subcutaneous Velcade administration for relapsed myeloma (http://bit.ly/gDI39Z).
Paper: Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA : Final Analysis of the IFM 2005-02.
ash.confex.com — “Paper: Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA : Final Analysis of the IFM 2005-02.” View full resource at ash.confex.com
Most Recently Shared on November 30, 2010 at 2:08 am By:
Robert Z. Orlowski Physician, Doctor, and Internist
Maintenance with Revlimid post-stem cell transplant added 18 months to progression-free survival in myeloma patients (http://bit.ly/dHoTRo).
Paper: Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based C
ash.confex.com — “Paper: Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH) and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated with A Bortezomib-Based Combination” View full resource at ash.confex.com
Most Recently Shared on November 30, 2010 at 2:05 am By:
Robert Z. Orlowski Physician, Doctor, and Internist
Older patients with high-risk myeloma (by cytogenetics) still have worse outcomes despite bortezomib-based therapy (http://bit.ly/e9ioGh).
Paper: Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma
ash.confex.com — “Paper: Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma” View full resource at ash.confex.com
Most Recently Shared on November 28, 2010 at 5:53 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Early treatment with zoledronic acid is associated with reduced risk of skeletal events in myeloma patients (http://bit.ly/dJE3le).
Paper: Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No
ash.confex.com — “Paper: Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment” View full resource at ash.confex.com
Most Recently Shared on November 28, 2010 at 5:44 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Revlimid + Dex shortened the time to progression of patients with smoldering myeloma to symptomatic disease (http://bit.ly/eEtD7T).
Paper: Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
ash.confex.com — “Paper: Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma” View full resource at ash.confex.com
Most Recently Shared on November 25, 2010 at 11:05 am By:
Robert Z. Orlowski Physician, Doctor, and Internist
Combination of Revlimid/Thalomid/Decadron: 92% response rate in relapsed or refractory (even to Revlimid) myeloma (http://bit.ly/fLJlBv).
Paper: A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma
ash.confex.com — “Paper: A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma” View full resource at ash.confex.com
Most Recently Shared on November 25, 2010 at 11:03 am By:
Robert Z. Orlowski Physician, Doctor, and Internist
Kinesin spindle protein inhibitor ARRY-520 active against relapsed and/or refractory myeloma in phase I trial (http://bit.ly/gDiyy5).
